pegylated Somatropin + pegylated Somatropin + Jintropin AQ

Phase 2Completed

1 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Growth Hormone Deficiency

Conditions

Growth Hormone Deficiency

Trial Timeline

May 1, 2006 → Feb 1, 2007

NCT ID

NCT01342146

About pegylated Somatropin + pegylated Somatropin + Jintropin AQ

pegylated Somatropin + pegylated Somatropin + Jintropin AQ is a phase 2 stage product being developed by Sun Pharmaceutical for Growth Hormone Deficiency. The current trial status is completed. This product is registered under clinical trial identifier NCT01342146. Target conditions include Growth Hormone Deficiency.

What happened to similar drugs?

11 of 20 similar drugs in Growth Hormone Deficiency were approved

Approved (11) Terminated (1) Active (9)

✅PEG-somatropinSun PharmaceuticalApproved

✅PEG-somatropin + PEG-somatropinSun PharmaceuticalApproved

✅Saizen® solution for injection (referred as Saizen®)MerckApproved

✅Saizen + SaizenMerckApproved

✅EverolimusNovartisApproved

✅somatropin + somatropin + somatropinNovo NordiskApproved

✅somatropin + placeboNovo NordiskApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01342146	Phase 2	Completed	May 1, 2006	Feb 1, 2007	Growth Hormone Deficiency

Competing Products

20 competing products in Growth Hormone Deficiency

See all competitors

Product	Company	Stage	Hype Score
Somatropin	Eli Lilly	Phase 3	40
Somatropin (recombinant deoxyribonucleic acid [rDNA] origin)	Eli Lilly	Pre-clinical	26
HER3-DXd	Daiichi Sankyo	Pre-clinical	26
Erlotinib	Astellas Pharma	Phase 2	27
radio-labeled naquotinib + naquotinib	Astellas Pharma	Phase 1	21
PEG-somatropin	Sun Pharmaceutical	Approved	39
PEG-somatropin + PEG-somatropin	Sun Pharmaceutical	Approved	39
PEG-somatropin	Sun Pharmaceutical	Phase 3	40
Somatropin + Somatropin	Eli Lilly	Phase 3	40
Somatropin + Somatropin	Eli Lilly	Phase 3	40
somatropin, rDNA origin, for injection	Eli Lilly	Phase 3	40
Sterile becaplermin gel vs. sterile placebo gel treatment 1	Johnson & Johnson	Pre-clinical	26
ABT-414	AbbVie	Pre-clinical	26
Saizen® A + Saizen® B	Merck	Phase 3	40
Saizen® solution for injection (referred as Saizen®)	Merck	Approved	43
Cetuximab + FOLFIRI (5-Fluorouracil, Folinic acid, Irinotecan)	Merck	Phase 3	40
Saizen + Saizen	Merck	Approved	43
Miransertib	Merck	Phase 2	39
Miransertib	Merck	Phase 1/2	24
ARX201 + ARX201 + ARX201	Merck	Phase 2	35